KYNB
KYNB
NASDAQ · Biotechnology

Kyntra Bio Inc

$7.00
+0.22 (+3.24%)
As of Apr 1, 3:51 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.57M
Net Income
187.23M
Gross Margin
91.4%
Profit Margin
2,848.6%
Rev Growth
-64.2%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 91.4% 91.4% 66.4% 66.4%
Operating Margin -814.9% -733.4% -24.8% -27.2%
Profit Margin 2,848.6% 2,706.2% -23.6% -26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.57M 18.38M 5.44M 5.56M
Gross Profit 6.01M 16.79M 3.61M 3.69M
Operating Income -53,560,245 -134,761,589 -1,347,007 -1,515,511
Net Income 187.23M 471.09M -1,283,535 -1,495,769
Gross Margin 91.4% 91.4% 66.4% 66.4%
Operating Margin -814.9% -733.4% -24.8% -27.2%
Profit Margin 2,848.6% 2,706.2% -23.6% -26.9%
Rev Growth -64.2% -64.2% +18.0% +2.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.06M 1.06M 11.14M 12.70M
Total Equity 12.60M 12.60M 24.70M 26.50M
D/E Ratio 0.08 0.08 0.45 0.48
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -52,795,958 -140,218,507 -2,024,078 -1,912,875
Free Cash Flow -1,099,827 -902,858